Titan Medical Inc. Also Trading on the Toronto Stock Exchange
Titan Medical Inc.’s (OTCQX: TITXF) stock volume soared Sept. 30 with 179,814 shares changing hands, significantly higher than its 30-day average volume of 160,694 shares.
The uptick in volume could be related to the Canadian robotic surgical company’s announcement that its common shares and warrants began trading on the Toronto Stock Exchange ("TSX") Sept. 30.
Concurrent with the TSX listing, Titan’s common shares and warrants will be de-listed from the TSX Venture Exchange.
Two Robotic Products Being Developed
There is not much information about this company, because it is basically in its developmental stage.
However, it is working feverishly on its Single Port Orifice Robotic Technology, SPORT™ Surgical System, that it says is comprised of a surgeon-controlled robotic platform that includes a 3D vision system and interactive instruments for performing MIS procedures.
This includes a workstation that provides the surgeon with an interface to the robotic platform for controlling the interactive instruments and providing a 3D endoscopic view of inside a patient's body during MIS procedures.
The SPORT(TM) Surgical System is being designed to expand robotic surgery into both simple and complex areas of surgical specialties and procedures that are currently under-serviced. It is also being designed to allow surgeons to perform procedures within small- to medium-size surgical spaces, such as general surgery and cholecystectomy.
How long and at what cost it will take to fully develop this product and bring it to market remains to be seen.
On Sept. 30, TITXF’s share value closed at $2.18, up 1 cent from its closing price of $2.19 the previous day.
Find out what could be the best investor’s move when it comes to TITXF by getting the complete report here or by cutting and pasting the following link in your Web browser:
OncoSec Medical to Present at 3 High-Profile Events
OncoSec Medical Inc.’s (OTCQB: ONCS) share volume picked up Sept. 30, with 1.2 million shares changing hands, but still lower than its 30-day average volume of 1.6 million shares.
The San Diego-based medical device manufacturer is not making any big news, but it does continue to churn out positive press releases.
Its latest, issued Sept. 30, OncoSec announced that the company’s top executives would attend or present at three events in October. The company's agenda includes a number of high-profile scientific and investment conferences, following a recent presentation of data at the ESMO 2014 Congress.
At the events, the company touts the potential effectiveness of its tumor-killing devices.
Latest Financials
OncoSec’s last quarterly report filed June 13, while not great, does show that the company has a good amount of cash on hand. This is of paramount importance for a company developing and promoting new products.
Here’s a summary of it latest quarter:
Cash and cash equivalents on hand of $24.2 millionNet loss of $3.8 million
Total liabilities of $1.1 million
No revenue
Net loss of $3.8 million
On Sept. 30, the share price of ONCS closed at 48 cents, down 2 cents from previous day‘s close of 50 cents.
Find out what could be the best investor’s move when it comes to ONCS by getting the complete report here or by cutting and pasting the following link in your Web browser:
Cellceutix Corp.’s upward Trend Continues
Cellceutix Corp.’s (OTCQB: CTIX) stock volume continued to soar Sept. 30, with 1.6 million shares changing hands, three times its 30-day average volume of 527,536.
This week-long surge comes on the heels of the Beverly, Mass.-based biopharma company reporting favorable results in a recently completed preclinical study evaluating its new antibiotic compounds against specific strains of multi-drug resistant Klebsiella pneumoniae.
New Data to Be Released
In the Sept. 19 announcement, the company said it was less than two months away from having top-line data from its Phase 2b trial of its antibiotic Brilacidin for acute bacterial skin and skin structure infections.
"If we achieve successful data from the recently completed Phase 2 trial, my hope is that people will understand defense in mimetic's potential," Cellceutix’s CEO Leo Ehrlich said, in a statement. "It's no longer a world class antibiotic drug, but a world class platform to fight serious public health threats," he added.
This news has helped fuel a multiday uptick in Cellceutix’s share value as well.
On Sept. 30, CTIX’s share price closed at $3.02, up 11 cents from previous day’s close of $2.91 a share.
Find out what could be the best investor’s move when it comes to ONCS by getting the complete report here or by cutting and pasting the following link in your Web browser:
ABOUT US:
www.sixfigurestockpicks.com issues momentum alerts on stocks that can provide gains to day traders.
www.sixfigurestockpicks.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.
www.sixfigurestockpicks.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals www.pennypickalerts.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the www.pennypickalerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: www.sixfigurestockpicks.com
Disclosure
www.sixfigurestockpicks.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.